Effects of a New Antibiotic, Isohematinic Acid, on the Resistance of Mice to Experimental Infections

Shiraishi, Akio; Katayama, Toshiaki; Matsuda, Tomoko; Itoh, Yoshio; Haneishi, Tatsuo

doi:10.1111/j.1348-0421.1987.tb03108.x

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the activities of some of these compounds are compared with that of LSN B, in our assay system (18), the effects of LSN B were stronger than those of MDP and isohematinic acid, and comparable with those of human recombinant G-CSF (data not shown). Therefore, LSN B could be a useful agent for the treatment of immunosuppressed patients, especially with leukopenia.…”

Section: Discussionmentioning

confidence: 97%

“…In preliminary experiments, daily administration of 0.3 mg/kg LSN B for five days resulted in a sixfold increase in peripheral neutrophils, but no ( FK-156) and isohematinic acid, which enhance the function of neutrophils and thereby augment host resistance to bacterial infection (4,8,13,18). When the activities of some of these compounds are compared with that of LSN B, in our assay system (18), the effects of LSN B were stronger than those of MDP and isohematinic acid, and comparable with those of human recombinant G-CSF (data not shown).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Augmentation of Host Resistance against Bacterial Infection by Treatment with Leustroducsin B, a New CSF Inducer

Kohama

Katayama²,

Inukai³

et al. 1994

Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

We tested the in vivo activity of leustroducsin B (LSN B), a new colony-stimulating factor (CSF) inducer isolated from the culture broth of Streptomyces platensis, with mice infected with Escherichia coli. Treatment with LSN B augmented the host resistance to lethal infection of E. coli at doses between 0.1 mg/kg and 1 mg/kg. Serum interleukin-6 (IL-6) levels were found to increase after this treatment, and superoxide anion generation of neutrophils was enhanced in vivo, suggesting that LSN B augmented the host resistance at least in part by inducing IL-6, which subsequently enhanced the bactericidal activity of the neutrophils.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Augmentation of Host Resistance against Bacterial Infection by Treatment with Leustroducsin B, a New CSF Inducer

Kohama

Katayama²,

Inukai³

et al. 1994

Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

Aladapcin, a new microbial metabolite that enhances host resistance against bacterial infection. Production, isolation, physico-chemical properties and biological activities.

Shiraishi

Nakajima²,

Kaxayama³

et al. 1990

J. Antibiot.

View full text Add to dashboard Cite

We have constructed a new screening system for detecting microbial products that enhance host resistance against bacterial infection. It was found that a new compound with such activity is produced by a soil isolate classified as Nocardia sp. SANK60484. The compoundwas isolated from the culture filtrate of the organism and namedaladapcin after its amino acid composition. Aladapcin was obtained as an amphoteric white amorphouspowder with the molecular formula, C13H25N5O5. It consists of 2mol of D-alanine and 1 mol of raeso-diaminopimelic acid. Fromthe analysis of IR, *H NMRand FAB-MS spectra, the structure was assigned to be a tripeptide. Aladapcin enhanced host resistance against an experimental Escherichia coli infection in mice at doses ranging between 1 and 100/ig/kg.Manyantibiotics have been used to protect hosts against invasion by infectious agents. However, if the resistance of the host has deteriorated for somereason such as age or treatment with cytotoxic antitumor agents, antimicrobial agents are not always effective. Therefore, we expect that a compound that is able to stimulate host resistance could be useful as another type of chemotherapeutic agent against infectious diseases. This paper deals with the fermentation, isolation and physico-chemical properties of aladapcin. The characteristics and identification of the producing organism will be published elsewhere. Screening SystemEscherichia coli SANK73175 was selected as an infectious pathogen to establish a good sensitive assay system in male ICR mice (5-week old, Japan CLEA, Tokyo), a system which positively demonstrated the enhancing activity ofisohematinic acid and BM12,531 1}. E. coli SANK73175 was grown in Trypticase soy broth for 17 hours at 37°C and the cells were harvested by centrifugation. After washing the cells two times with strerilized physiological saline, the cells were resuspended in physiological saline and served for the challenge. Usually when mice were infected with 2 x 108 cells of E. coli SANK73175 intravenously, all of the mice died within 3 days. Therefore, we observed the number of dead and surviving mice for a period of 7 days after the infection. Groups in which the meansurvival time was more than twice of that of the control mice were evaluated as positive. Then we examined the effect of microbial culture media on the assay system. When0.2-ml portions

show abstract

Effects of a New Antibiotic, Isohematinic Acid, on the Resistance of Mice to Experimental Infections

Cited by 2 publications

References 15 publications

Augmentation of Host Resistance against Bacterial Infection by Treatment with Leustroducsin B, a New CSF Inducer

Augmentation of Host Resistance against Bacterial Infection by Treatment with Leustroducsin B, a New CSF Inducer

Aladapcin, a new microbial metabolite that enhances host resistance against bacterial infection. Production, isolation, physico-chemical properties and biological activities.

Contact Info

Product

Resources

About